Sorbinil Explained

Sorbinil (INN) is an aldose reductase inhibitor being investigated for treatment of diabetic complications including neuropathy and retinopathy.^[1] Aldose reductase is an enzyme present in lens and brain that removes excess glucose by converting it to sorbitol. Sorbitol accumulation can lead to the development of cataracts in the lens and neuropathy in peripheral nerves. Sorbinil has been shown to inhibit aldose reductase in human brain^[2] and placenta^[3] and calf^[4] and rat lens. Sorbinil reduced sorbitol accumulation in rat lens and sciatic nerve of diabetic rats orally administered 0.25 mg/kg sorbinil.

Notes and References

1. 21129963 . 2011 . MacCari . R . Del Corso . A . Giglio . M . Moschini . R . Mura . U . Ottanà . R . In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors . 21 . 1 . 200–3 . 10.1016/j.bmcl.2010.11.041 . Bioorganic & Medicinal Chemistry Letters.
2. O'Brien MM. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil. J Neurochem. 1982. 39. 3 . 810–4. 6808090. etal. 10.1111/j.1471-4159.1982.tb07964.x. 22368580 .
3. Kinoshita JH. Aldose reductase in diabetic complications of the eye. Metabolism. 1979. 28. suppl 1. 462–9. 45423. etal. 10.1016/0026-0495(79)90057-x.
4. Peterson MJ. CP45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.. Metabolism. 1979. 28. Suppl 1. 456–61. 122297. etal. 10.1016/0026-0495(79)90056-8.